Steris
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
436% more call options, than puts
Call options by funds: $8.59M | Put options by funds: $1.6M
17% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 78
0% more funds holding
Funds holding: 749 [Q3] → 750 (+1) [Q4]
2.4% less ownership
Funds ownership: 95.21% [Q3] → 92.81% (-2.4%) [Q4]
13% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 7 (-1) [Q4]
16% less capital invested
Capital invested by funds: $22.5B [Q3] → $18.8B (-$3.67B) [Q4]
17% less repeat investments, than reductions
Existing positions increased: 251 | Existing positions reduced: 303
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$240
6%
upside
Avg. target
$257
14%
upside
High target
$265
17%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Reni Benjamin 14% 1-year accuracy 5 / 37 met price target | 17%upside $265 | Market Outperform Reiterated | 6 Feb 2025 |
Stephens & Co. Jacob Johnson 29% 1-year accuracy 4 / 14 met price target | 6%upside $240 | Overweight Reiterated | 6 Feb 2025 |
Piper Sandler Jason Bednar 32% 1-year accuracy 12 / 37 met price target | 17%upside $265 | Overweight Maintained | 3 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments.
Positive
Zacks Investment Research
3 weeks ago
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Neutral
Zacks Investment Research
1 month ago
Steris (STE) International Revenue in Focus: Trends and Expectations
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Neutral
Seeking Alpha
1 month ago
STERIS plc (STE) Q3 2025 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Officer Dan Carestio – President and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Brett Fishbin – KeyBanc Michael Polark – Wolfe Research Jason Bednar – Piper Sandler Patrick Wood – Morgan Stanley Mike Matson – Needham & Company Dave Turkaly – Citizens Operator Good day, and welcome to the STERIS plc Third Quarter 2025 Conference Call. All participants will be in a listen-only mode.
Positive
Zacks Investment Research
1 month ago
STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.
Positive
Zacks Investment Research
1 month ago
Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
1 month ago
Steris (STE) Matches Q3 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.22 per share a year ago.
Negative
Reuters
1 month ago
Steris lowers annual profit forecast due to a stronger dollar
Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar.
Neutral
GlobeNewsWire
1 month ago
STERIS Announces Financial Results for Fiscal 2025 Third Quarter
DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%.
Positive
Zacks Investment Research
1 month ago
Can Steris (STE) Keep the Earnings Surprise Streak Alive?
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Charts implemented using Lightweight Charts™